ArticleDiscover oncology2025
Regulation of carbonic anhydrase IX gene expression through the LncRNA TRPM2-AS is associated with tumor progression in colorectal tumors.
Article in Discover oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveCarbonic anhydrase IX (CAIX) expression in tumors is induced in response to hypoxia leading to loss of cellular adhesion and tumor cell progression. This study was pursued to identify a specific long non-coding RNA for targeting CAIX in colorectal cancer (CRC) and its consequence on cancer cell features.
methodsThrough bioinformatics, CAIX gene was selected to identify non-coding RNAs associated with CAIX. Then the expression of CAIX-specific mRNA and the lncRNA were compared in human CRC biopsies (n = 50) and their normal adjacent biopsies using quantitative real-time polymerase chain reaction (qRT-PCR). CAIX expression was evaluated in HCT116 cell line after blocking the lncRNA by Antisense Oligonucleotide (ASO). Expression of the target genes and cellular behavior; cell proliferation rate, apoptosis, cell migration and invasion were examined.
resultsLncRNA-TRPM2-AS and CAIX expressions were markedly higher (> 8 fold) in CRC malignant tissues compared to normal adjacent tissues. This increase was more in stage II/III tumors. Blocking lncRNA TRPM2-AS expression in HCT116 cell line resulted in ~ 50% suppression in CAIX expression, as well as inhibition in cell proliferation and migration. Accordingly, the rate of cell death was enhanced in the cancer cells.
conclusionsLncRNATRPM2-AS can efficiently control hypoxia in CRC cells by targeting CAIX. This is evidenced by showing the overexpression of lncRNA and CAIX in CRC tumors as well as the suppressive effects of lncRNA TRPM2-AS on CAIX expression in the HCT116 cell line. This data suggests CAIX down-regulation by lncRNA TRPM2, as a therapeutic target to suppress hypoxia-related progression and drug resistance in tumor cells.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.